Loading…
Loading…
EQUITY / NYSE · XASE
NanoViricides, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →01/01/2026 – 03/31/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.43 USD · -1.3793%
Observed: Oct 5, 2026, 11:27 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/05/2026 · 1.45 USD · Volume 708,559
63 actual observations · Latest bar: 2026-10-05 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2026 – 03/31/2026 · Units
| Metric | 2026 / Quarter 3 | 2025 / Quarter 3 | Change |
|---|---|---|---|
| Operating profit | -2,030,218 USD | -2,249,156 USD | — |
| Net income | -1,989,333 USD | -2,216,783 USD | — |
| Cash and cash equivalents | 3,213,256 USD | — | — |
| Total liabilities | 1,100,000 USD | — | — |
| Total equity | 9,153,597 USD | 8,833,049 USD | +3.63% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 207/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 306/30/2025 – 06/30/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2024 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 03/31/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,213,256 USD | — | — | — | — | 1,558,564 USD | 1,558,564 USD | — |
| Net incomeIncome statement | -1,989,333 USD | -5,995,110 USD | -2,220,719 USD | -4,005,777 USD | -1,785,058 USD | — | -9,466,966 USD | -2,216,783 USD |
| Operating profitIncome statement | -2,030,218 USD | -6,060,077 USD | — | -4,029,859 USD | — | — | -9,591,645 USD | -2,249,156 USD |
| Total assetsBalance sheet | 10,219,004 USD | — | — | — | — | 8,824,085 USD | 8,824,085 USD | — |
| Total equityBalance sheet | 9,153,597 USD | — | 11,071,715 USD | — | 7,174,694 USD | 7,517,566 USD | 7,517,566 USD | 8,833,049 USD |
| Total liabilitiesBalance sheet | 1,100,000 USD | — | — | — | — | — | 1,300,000 USD | — |
| Capital expendituresCash flow statement | — | 84,316 USD | — | 84,316 USD | — | — | 56,964 USD | — |
| Financing cash flowCash flow statement | — | 7,313,102 USD | — | 7,319,844 USD | — | — | 5,296,429 USD | — |
| Investing cash flowCash flow statement | — | -84,316 USD | — | -84,316 USD | — | — | -56,964 USD | — |
| Operating cash flowCash flow statement | — | -5,574,094 USD | — | -3,643,512 USD | — | — | -8,478,679 USD | — |
| Report source | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 02/17/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 09/29/2025 | Open report ↗ Published: 05/15/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.